Uveitis specialist Lana Rifkin, MD, presented results from the TRS4 Vision trial at the 26th annual American Uveitis Society Winter Symposium in Park City, Utah. The trial evaluated the safety and efficacy of TRS01 eye drops in the treatment of active non-infectious anterior uveitis, a potentially blinding autoimmune eye inflammation, considered the third leading cause of blindness in the developed world.
“We are grateful for Dr. Rifkin’s expertise and dedication as she presented the TRS4Vision trial results.” Tarsier Pharma stated. “Her role as a uveitis expert and investigator in the trial has been invaluable. Thank you, Dr. Rifkin, for advancing our mission to bring TRS01 to patients in need.”
TRS01 (dazdotuftide), manufactured by Tarsier Pharma, is a potent steroid-free immunomodulatory agent, administered topically for the treatment of noninfectious anterior uveitis. It is particularly being studied in patients with uveitic glaucoma, a potentially blinding outcome for some patients with severe uveitis. These patients are especially vulnerable to the potential side effects of traditional treatment with steroids, including increased intraocular pressure which may exacerbate glaucoma and expedite vision loss.
“TRS01 has the potential to break the vicious cycle that leads to vision loss and blindness associated with uveitic glaucoma,” Dr. Rifkin said.
In a social media post marking the research milestone, Tarsier Pharma stated, “We are grateful for Dr. Rifkin’s expertise and dedication as she presented the TRS4Vision trial results.” Tarsier Pharma stated. “Her role as a uveitis expert and investigator in the trial has been invaluable. Thank you, Dr. Rifkin, for advancing our mission to bring TRS01 to patients in need.”
OCB congratulates Dr. Rifkin for her role in advancing the treatment possibilities for patients with severe uveitis.
